

## SYNLAB Agreements Signed in Italy and Portugal

- In October, Microba and SYNLAB executed a major amendment to a master agreement between the companies to enable distribution expansion across Europe and Latin America
- Aligned to the amendment, new agreements have been executed with SYNLAB affiliate organisations across Italy and Portugal
- Italy is the third largest probiotic market in the world (by sales), highlighting the awareness of gut health and making it a key market for microbiome testing

**Microba Life Sciences Limited** (ASX: MAP) ("Microba") is pleased to announce that agreements have been executed with SYNLAB International GmbH ("SYNLAB") (ETR: SYAB) affiliate organisations Synlab Italia Srl and SYNLABHEALTH II S.A., to distribute Microba's testing technology into Italy and Portugal.

In 2020, Microba entered into a master agreement with SYNLAB International GmbH and an agreement with SYNLAB Diagnosticos Globales to deliver Microba's testing to Healthcare Providers in Spain, with an option to formalise distribution agreements across their affiliate organisations, which operate in 36 countries. With positive sales and customer feedback in Spain, in October 2022 SYNLAB further activated their rights through an amendment to the master agreement with Microba to pursue formal expansion into additional countries across Europe and Latin America.

Aligned to this, a first group of new agreements have now been signed with SYNLAB affiliate organisations Synlab Italia Srl and SYNLABHEALTH II S.A. for Italy and Portugal respectively. The agreement in Italy provides two years of exclusive distribution rights for Healthcare Providers, and then non-exclusive distribution rights out to 31 December 2028. Italy is the third largest market in the world for probiotic sales, highlighting the awareness of gut health and making it a key market for Microba's microbiome testing. The agreement in Portugal provides non-exclusive distribution rights for Healthcare Providers out to 31 December 2028.

Entry into both Italy and Portugal, two important European markets, represents another positive advancement in distribution with Europe's largest medical diagnostics company. More affiliate country agreements are anticipated to be completed in the near term to continue this rapid expansion activity with SYNLAB.

**Microba's Senior Vice President - Services, Mr Bernie Woodcroft** said, *"I am pleased by our recent progress in distribution expansion with SYNLAB, Europe's largest medical diagnostics company. Italy represents a major market for gut health and the microbiome, and we are excited to get our testing into the hands of clinicians and patients across these two regions".*

*This announcement has been authorised for release by the Chairman and Chief Executive Officer.*

For further information, please contact:

**Dr Luke Reid**  
Chief Executive Officer  
E: Luke.Reid@microba.com

**Simon Hinsley**  
Investor / Media Relations  
E: simon@nwrcommunications.com.au  
T: +61 401 809 653

**About SYNLAB**

SYNLAB Group is the leader in medical diagnostic services and specialty testing in Europe. The Group offers a full range of innovative and reliable medical diagnostics to patients, practising doctors, hospitals and clinics, governments and corporates. SYNLAB operates in 36 countries across four continents and holds leading positions in most markets, regularly reinforcing the strength of its network through a proven acquisition strategy. Around 30,000 employees, including over 2,000 medical experts, contribute every day to the Group's worldwide success.

**About Microba Life Sciences Limited**

Microba Life Sciences is a precision microbiome company driven to improve human health. With world-leading technology for measuring the human gut microbiome, Microba is driving the discovery and development of novel therapeutics for major chronic diseases and delivering gut microbiome testing services globally to researchers, clinicians, and consumers. Through partnerships with leading organisations, Microba is powering the discovery of new relationships between the microbiome, health and disease for the development of new health solutions.

**For more information visit: [www.microba.com](http://www.microba.com)**

Microba encourages all current investors to go paperless by registering their details with the designated registry service provider, Automic Group.